Radionetics Oncology Emerges from Crinetics Pharmaceuticals with a Platform and Deep Pipeline of Nonpeptide Targeted Radiopharmaceutical Drug Candidates for Precision Oncology

NEXT STORY
Paratek Pharmaceuticals Announces Enrollment of First Patient in Phase 2b Study Evaluating NUZYRA® (omadacycline) for Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc)
PREV STORY
New to The Street TV Announces its Five Corporate Interviews Airing on Fox Business Network, Tonight, Monday, October 18, 2021, at 10:30 PM P.T. and Tomorrow Night, Tuesday, October 19, 2021, at 10:30 PM PT
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

How to Treat Minor Cuts; American Academy of Dermatology

ROSEMONT, Ill., July 10, 2018 (GLOBE NEWSWIRE) -- Cuts from a sharp knife or ...

author_avatar
NASDAQ Market News

100,000 Orion Corporation A shares converted into B shares

  ORION CORPORATION      STOCK EXCHANGE RELEASE 5 OCTOBER 2016 at 9.00 a.m. EEST               ...

author_avatar
NASDAQ Market News

Calithera Biosciences to Report Second Quarter 2017 Financial Results on Tuesday, August 8, 2017

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), ...

author_avatar
NASDAQ Market News